Corporate Update – Surgery Partners, Inc. (SGRY)
Surgery Partners, Inc. (SGRY) finished the most recent 24‑hour trading window at a modest decline of 0.58 %, closing at USD 15.40 as of 11:58 AM Central Europe on Thursday, 22 March 2026. The stock is presently available at roughly USD 15.4 on the most liquid exchanges, with an outstanding supply of 129.8 million shares. At this level, the company’s market capitalization sits near USD 2.0 billion.
Key trading metrics for the past day:
| Metric | Value |
|---|---|
| Volume traded in last 24 h | USD 36.3 million |
| 200‑day simple moving average | USD 14.44 |
| 52‑week high | USD 23.44 (29 Oct 2025) |
| 52‑week low | USD 11.41 (30 Mar 2026) |
| Month‑end change | ‑2.53 % |
The decline aligns with broader market softness, yet Surgery’s valuation remains resilient given its diversified portfolio of surgical facilities, physician‑partnered hospitals, diagnostic laboratories, and ancillary services across the United States.
Peer Performance (24‑Hour View)
| Company | Ticker | Change | Current Price | Market Cap | P/E (if available) |
|---|---|---|---|---|---|
| Pitney Bowes | PBI | +0.17 % | USD 17.40 | USD 2.4 billion | 14.21 |
| Kennametal | KMT | ‑0.32 % | USD 31.11 | USD 2.4 billion | 7.05 |
| Perpetua | PPTA | +0.11 % | USD 18.74 | USD 2.4 billion | — |
| Nuscale Power | SMR | ‑1.43 % | USD 5.50 | USD 2.4 billion | — |
| Supernus | SUPN | ‑0.05 % | USD 41.21 | USD 2.4 billion | — |
Nuscale Power (SMR)
The Canadian nuclear‑technology firm is poised to release its latest quarterly results on 5 November 2026, covering the period ending 30 September 2026. Forecasts project a modest earnings‑per‑share improvement versus the same quarter last year, which recorded a significant loss. Revenue, however, is expected to decline markedly. Analysts anticipate a narrower loss per share for the full fiscal year, with annual revenue projected to fall noticeably from last year’s level. The forthcoming report will clarify these expectations.
Supernus (SUPN)
Supernus has secured a seven‑year orphan‑drug exclusivity for its Parkinson’s disease therapy ONAPGO (apomorphine) following FDA approval on 3 February 2025. The company is also filing a supplemental New Drug Application to establish a second supplier, targeting approval by mid‑2027. The resolution of a prior supply issue underscores Supernus’s commitment to uninterrupted access to its Parkinson’s therapies.
Forward‑Looking Perspective
Surgery Partners’ robust infrastructure and integrated care model position it well to capitalize on the continued demand for outpatient and minimally invasive procedures. The firm’s diversified revenue streams—from surgical services to ancillary offerings—mitigate sector‑specific risks and provide a stable cash‑flow foundation. While short‑term market volatility has weighed on the stock, the underlying business fundamentals remain strong, suggesting a rebound as healthcare utilization normalizes.
Investors should monitor:
- Operating margins across Surgery’s facility portfolio, particularly in high‑volume regions.
- Capital‑expenditure plans for expanding diagnostic and ancillary services.
- Regulatory developments that could impact reimbursement for outpatient procedures.
In sum, despite a slight dip in the current trading session, Surgery Partners continues to demonstrate disciplined management, a resilient operating model, and a clear path to value creation for shareholders.
